Prof Dean Naisbitt BSc, PhD

Senior Lecturer Molecular and Clinical Pharmacology


    Personal Statement

    I am currently employed as a Senior Lecturer in the MRC funded Centre for Drug Safety Science at the University of Liverpool. The main focus of my research group is investigation and definition of the relationship between the chemistry of antigen formation and the mechanisms by which this leads to an aberrant T-cell-mediated immune response in man. My research group is composed of 2 post-doctoral research fellows, 6 PhD students and 1 research technician. The research carried out in my laboratory adds an extra dimension to the on-going research in the Centre for Drug Safety Science, which is directed by Professor B. Kevin Park.
    Key Achievements

    • Position Held – Senior Lecturer in Pharmacology, The University of Liverpool
    • Research Group – 2 post-doctoral research fellow, 6 PhD students, 1 research technicians
    • Research Areas – (1) Investigation of the cellular mechanisms of hypersensitivity reactions to drugs and chemicals. (2) Definition of the mechanism(s) by which drugs interact with immune cells. (3) Evaluation of the T-cell stimulatory capacity of peptide vaccines under development for the treatment of pancreatic cancer. Published over 65 peer-reviewed articles in international recognized journals including Molecular Pharmacology, The Journal of Immunology and Journal of Allergy and Clinical Immunology
    • Prizes – Awarded 13 prizes for achievements in research and academia, including, the British Toxicology Society Young Investigator award in 2003, the British Pharmacological Society Bill Bowman Travelling Lectureship in 2005 & the ISSX New Investigator Award in 2009.
    • Invitations to speak – Invited to present a research paper at 40 national or international meetings

    Personal Distinctions

    • BPS Novartis prize in Pharmacology (Prize, British Pharmacology Society 2012)
    • Nomination for Fellowship of Society (Competitive Fellowship, British Pharmacology Society 2012)
    • Immune mediators in DILI: Lessons to be learned from studies with human cells. (Invitation to Speak, Joint MDO/ISSX Meeting Amsterdam 2011)
    • Chemical Research in Toxicology Young Investigator Award (the ACS Publications journal Chemical Research in Toxicology in collaboration with the ACS Division of Chemical Toxicology 2011)
    • Should the hapten hypothesis be used in 2011 to define the chemical basis of immune-mediated .... (Invitation to Speak, Gordon Conference on Drug Metabolism, New Hampshire, USA. 2011)
    • Development of in vitro T-cell methods to predict the sensitizing potential of drugs (Invitation to Speak, SENSITIV meeting, Brussels, Belgium 2011)
    • The role of the adaptive immune system in drug-induced liver injury (Invitation to Speak, The Liver Meeting, San Francisco, USA 2011)
    • Novel Challenges in Cystic Fibrosis Infection (Invitation to Speak, European Cystic Fibrosis Society, Valencia, Spain 2011)
    • The chemical reactivity, antigenicity and immunogenicity of p-phenylenediamine. (Invitation to Speak, 10th Congress of the ESCD, Strasburg, France 2010)
    • The ISSX European New Investigator Award & the ESBP Founders Lecture in Honour of Karl Netter (ISSX 2009)
    • The Chemical and Cellular basis of drug hypersensitivity. (Invitation to Speak, St Thomas’s Hospital, London, UK. 2009)
    • The role of the immune system in adverse drug reactions. (Invitation to Speak, ESF-UB Conference Pharmacogenetics and Pharmacogenomics, Barcelona, Spain 2009)
    • The role of metabolism in immune-mediated allergic reactions (Invitation to Speak, AAAAI Annual Meeting, Washington DC, USA. 2009)
    • e role of metabolism in T-cell mediated drug hypersensitivity reactions (Invitation to Speak, 46th Congress of the European Societies of Toxicology 2009)
    • The ISSX European New Investigator Award & the ESBP Founders Lecture in Honour of Karl Netter, (Invitation to Speak, European ISSX meeting, Lisbon, Portugal 2009)
    • Drug Allergy, clinical and fundamental aspects. (Invitation to Speak, Surrey, UK 2009)
    • The Chemical basis of drug-induced allergic reactions. (Invitation to Speak, International Conference on Dermatotoxicology, Aachen, Germany 2009)
    • The role of T-cells in drug-induced allergic reactions. (Invitation to Speak, Leeds Universtiry 2009)
    • Basic mechanisms of drug hypersensitivity (Invitation to Speak, 4th International Drug Hypersensitivity Meeting 2009)
    • Drug metabolism and allergy (Invitation to Speak, Conference: New Trends in Paediatric Asthma and Allergy, London, UK 2009)
    • BSTP Education Module on the Lymphoid/Haemopoietic System (Invitation to Speak, Cambridge University 2007)
    • Dendritic cell signaling and drug hypersensitivity (Invitation to Speak, ERGECD meeting 2007)
    • Chemical and cellular mechanisms of drug hypersensitivity (Invitation to Speak, University of Western Ontario, Canada 2007)
    • Role of Metabolism in Drug Hypersensitivity (Invitation to Speak, Aachen, Germany 2007)
    • Chemical Mechanisms of Allergic Contact Dermatitis (Invitation to Speak, University of London 2007)
    • Mechanisms of Drug Hypersensitivity (Invitation to Speak, North East Immunology Society 2007)
    • Drug Allergy, clinical and fundamental aspects. (Invitation to Speak, The University of Surrey 2007)
    • Lecturer, International symposium of adverse drug reactions, Yokohama, Japan (Invitation to Speak, Japanese Society of Allergy and Immunology 2006)
    • 2nd Drug hypersensitivity meeting, Liverpool, UK (Invitation to Speak, The University of Liverpool 2006)
    • ITCASS meeting, Manchester, UK (Invitation to Speak, ITCASS society 2005)
    • Bill Bowman Travelling Lecturer (British Pharmacological Society 2005)
    • 3 lectures to be arranged at industrial or academic venues in the UK. A condition of the Bill Bowman (Invitation to Speak, bish Pharmacological Society 2005)

    Untitled Document